Provenance and funding of extremely cited biomedical papers published in 2003-2004, 2013-2014 and 2023-2024

John P.A. Ioannidis, MD, DSc

Departments of Medicine, of Epidemiology and Population Health, and of Biomedical Data Science, and Meta-Research Innovation Center at Stanford (METRICS), Stanford University, Stanford, CA, USA

Short title: Funding of extremely cited biomedical papers

Date: April 16, 2025

Correspondence: John P.A. Ioannidis, MD, DSc, 3180 Porter Drive, Room A129, Stanford Research Park, Palo Alto CA 94304, USA. E-mail: jioannid@stanford.edu

Funding: The work of John Ioannidis is supported by an unrestricted gift from Sue and Bob O'Donnell to Stanford.

Competing interest statement: My work is currently supported in part by an R01 grant unrelated to the current work. I am a co-author in 2 of the 300 analyzed papers and in an update of a third paper.

Data sharing statement: All data are in the manuscript and in the supplementary tables.

Contributions: JPAI had the idea, collected the data, analyzed the data, and wrote the paper.

Keywords: research funding, NIH, bibliometrics, biomedical research, USA, China

Word count: 2,822; 42 references; 4 tables; 3 supplementary tables; abstract: 349 words.

ABSTRACT

Importance: It is important to monitor changes in biomedical literature and its funding. China has surpassed the USA in publications and, in some analyses, also in some impact indicators.

Objective: To evaluate changes over time in the profiles of the most highly cited biomedical papers.

Design: The 100 top-cited biomedical papers (based on Scopus) published in each of three time periods (2003-4, 2013-4, and 2023-4) were assessed for corresponding authors, types of publications represented, and funding sources, with emphasis on funding from the US National Institutes of Health (NIH) that has been traditionally considered the major funder of biomedical research.

Setting: Global.

Participants: not relevant

Exposures: not relevant

Main outcome measures: Provenance and funding sources.

Main findings: Corresponding authors from the USA decreased overtime (59/100 papers in 2003-4, 58/100 in 2013-4, 45/100 in 2023-4). China had corresponding authors in 0,1, and 4 top cited papers in the three time periods, respectively. There was a marked increase in consensus items (10/100 in 2003-4 versus 24/100 in 2023-4) and in reference statistics papers (1/100 in 2003-4, 10/100 in 2013-4, 11/100 in 2023-4). Reviews remained common among top cited papers, but almost always they were non-systematic. NIH funding was listed in 45/100, 50/100, and 23/100 papers in the three time periods, respectively. All other

countries combined surpassed US public funding in 2023-4. Funding by NIH alone decreased sharply in the last decade (32/100, 28/100, and 2/100 in the three time periods, respectively). More commonly listed funding from non-profit organizations, societies, and institutions complemented the NIH funding decline. The first authors of 7/45 and the corresponding author(s) of 14/45 top cited USA-based papers of 2023-4 were listed as leaders of active NIH grants in RePORTER as of February 2025. Citation gaming became more obvious in 2023-4.

Conclusions and relevance: Overall, the USA remains a world leader regarding the most highly cited biomedical research and NIH funding retains a substantial presence among top cited papers. However, NIH influence has shrunk overall, and top cited papers funded exclusively by NIH have almost disappeared. Strengthening public funding is essential to secure research serves the common good.

The landscape of biomedical publications is changing over time in volume and provenance. The USA has long generated the majority of both overall publications and high-impact work. However, China now ranks first in numbers of annual publications, spends more on R&D and has more researchers (1-3). Some analyses have shown that in 2022 China outperformed the USA even in number of papers published in the 82 high-quality journals of the Nature Index (4); and excelled also in numbers of papers in top 1% of citations (5). Concurrently, major changes and challenges have emerged in research funding and the publication ecosystem. The US National Institutes of Health (NIH) have traditionally been the major public funder of biomedical research, but its budget has barely caught up with inflation and is currently threatened with major cuts (6). Concurrently, as publication numbers have increased rapidly, most investigators have struggled to secure funding from diverse sources. Publishers have large profit margins from a burgeoning publication market (7) that is subject to gaming forces on journal impact factors (8). Journals may also be willing to publish more papers that concentrate extremely high citations (9). Diverse gaming practices abound (10,11).

The current analysis aims to examine the most extremely cited biomedical papers published in 2003-2004, in 2013-2014 and most recently in 2023-2024. The following questions are asked: What is the provenance of these papers and what types of papers reached the extremes of citation distributions? Has the dominance of the USA indeed decreased and has China overtaken the USA in these citation extremes? What are the funding sources of these extremely cited papers? More specifically, has NIH continued to

be the major funder of that work? Finally, might some of these extremely cited papers

reflect citation gaming?

Methods

Search strategy and eligible papers

The analysis of Scopus data (12) is exploratory, and no protocol was pre-registered.

No IRB approval was requested as it is a bibliometric analysis using public bibliometric

data and there is also no reporting guideline for such studies. Only full papers were

considered (Scopus categories of Articles, Reviews, and Conference Papers). Two periods

were considered initially: full papers published in 2003-2004 and those published in 2023-

2024. However, with stark differences observed, a third cohort of full papers published in

2013-2014 was added to probe whether changes were gradual. Searches for the first two

cohorts were performed on January 24, 2025, and for the 2013-2014 cohort a month later.

For each calendar period, all papers were ordered in decreasing number of citations

received. Starting from the most-cited, publications were screened to identify those

relevant to biomedicine and the top 100 most highly cited biomedical papers were thus

retrieved for each of the time periods. Publications were deemed relevant to biomedicine if

they belonged to any of the following Scopus subject areas: Medicine; Biochemistry,

Genetics and Molecular Biology; Pharmacology, Toxicology and Pharmaceutics;

Immunology and Microbiology; Neuroscience; Nursing; Health Professions; Veterinary;

Dentistry. Papers catalogued in other subject areas by Scopus could be included only if

they were deemed to have a major primary biomedical interest.

Data extraction and definitions

For the three batches of 100 eligible papers each, meta-data were exported from Scopus on bibliographic information, citations, funding information, corresponding authors and their addresses. Moreover, full texts were downloaded to verify the Scopus extracted information and to complement missing information not captured by Scopus.

Country of origin was assigned based on the country of the corresponding author(s). The eligible papers were classified into the following types: Primary research: resources and methods (including new software, databases, methods [statistical, computational, or other] and tools); primary research: other; reviews; consensus items (including guidelines, recommendations, consensus documents, and definitions); and reference statistics for diseases and conditions. Funding was classified in the following categories: NIH; other US federal/public (e.g. NSF, DOE, CDC); other government/public from other countries; non-profit (e.g. Gates or Welcome Trust); for-profit (e.g. pharma or tech companies); societies (e.g. American Heart Association); and institutional (e.g. universities). When funding was listed from multiple categories, all of them were captured. Specifically for papers with listed NIH funding, they were also categorized as listing only NIH funding; or listing additional funders.

Main outcomes

The main outcomes of interest are descriptive and include provenance (country of corresponding author), type of paper, type of funding, overall NIH funding, and NIH funding as sole funding source.

Furthermore, for the 2023-4 cohort, the first authors and the corresponding authors of papers with a USA corresponding author were assessed in NIH RePORTER (13) to see if they were listed as of February 2025 as the leader of any NIH grants.

Finally, it was assessed whether any of these highly cited papers had atypical features: >20% of the citations derived from a single journal; journal subject matter and/or title not representing the content of the article; or retraction (per Retraction Watch database) (14).

This project was aimed upfront to be descriptive without testing hypotheses with statistical tests.

Results

Scientific literature and identification of top cited biomedical papers

China was close to the USA in productivity by 2013-4 and had almost double the USA productivity in 2023-4 across the entire scientific literature, but the difference was more modest for the biomedical literature (Table 1). For all three time periods, biomedical papers accounted for most of the extremely cited papers across science. One had to screen 190, 185, and 162 top cited papers from 2003-4 , 2013-4, and 2023-4, respectively, to identify 100 biomedical ones.

Characteristics of the top cited biomedical papers (Table 2)

Details on the 100 most cited biomedical papers published in each of the three time periods appear in supplementary tables 1,2, and 3. A clear majority of papers in the 2003-4 cohort (59/100) and 2013-4 cohort (58/100) had USA corresponding authors, while in the 2023-4 cohort only 44/100 had USA corresponding authors. In the 2023-4 cohort there

were 7 other countries with corresponding authors in at least 4 papers (6/7 European) versus only 3 such countries in earlier cohorts. 18 papers had corresponding authors from multiple countries in the 2023-4, while this was not seen in the 2003-4 cohort and had occurred only twice in the 2013-4 cohort. China had corresponding authors for 4 papers in 2023-4, 1 (in Hong-Kong) in 2013-4, and none in 2003-4. Besides China, 2 other non-high-income countries (India and Russia) also had 1 top cited paper each in 2013-2014, and 5 other non-high-income countries had corresponding authors in at least 1 paper in 2023-4 (India 2 papers, 1 paper each for Colombia, N. Cyprus, Jordan, Malaysia). Conversely, all papers in 2003-4 had corresponding authors from high-income countries.

In 2003-4, two-thirds were primary research papers, equally split between "Resources and methods" work and other primary research. There were 23 reviews, of which only one aimed to be systematic;10 consensus items; and 1 reference statistics paper. The representation of primary research papers decreased gradually over time (55/100 in 2013-4 and 37/100 in 2023-4), relatively equally split between "Resources and methods" and other work. Reviews retained a considerable proportion, with almost all of them being non-systematic. Over a third of the top cited papers in the 2023-4 cohort were either consensus items (n=24) or reference statistics (n=11) with the increase in these types of papers noticed partly even in the 2013-2014 cohort.

Funding of top cited papers

NIH was the leading single governmental funder in all three time cohorts, but the number of top cited papers with any listed NIH funding decreased in the last decade and became half in the 2023-4 cohort versus in the 2003-4 cohort or 2013-4 cohort (23 versus

45 or 50, respectively) (Table 3). When limited to primary research, NIH was listed as a funder in 15/37, 33/55, and 32/66 top cited papers, respectively, in these three periods.

In 2023-4, all other countries combined exceeded NIH and other US federal agencies in top cited papers. All European countries combined matched NIH in 2023-4, while China only funded 3 top cited papers. In 2023-4, there were large increases in numbers of top cited papers funded by non-profit organizations and those listing institutional support, and even more so for papers supported by societies. Some of this increase was seen already in 2013-4 and accentuated in the following decade.

In 2003-4, a substantive majority (32/45) of NIH-funded papers did not list any other funders and this remained true in 2013-4 (28/50) (Table 4). Conversely, there were only 2/23 NIH-funded papers that did not list any other funders in the 2023-4 cohort. Co-funding with non-profit organizations was common in all cohorts, but in 2023-4 there was also common co-funding with for-profit entities, public/government funding from other countries, and listed institutional support, which were less common in earlier time periods.

Current NIH funding for first and corresponding authors

Of the 45 top cited papers of 2023-4 with USA-based corresponding authors, in 7 (16%) the first author was listed in RePORTER as leading some currently active NIH grant(s). The same was true for at least one of the corresponding authors in 14 papers (31%).

Atypical papers

One paper in 2023 was a guideline for reporting surgical case reports and >98% of its citations had been received by the publishing journal which indeed publishes many

surgical case reports. Another paper in 2023 was published in a Chemistry journal, and the title suggested that it was providing cancer statistics and projections to 2030, but the content was a review of diverse cancers without substantive epidemiological projections. Apparently, the paper was heavily cited by authors who mistook it for other regularly updated papers on cancer statistics. No top cited papers in any time cohort had been retracted.

Discussion

Biomedical research represents the majority of the most highly cited scientific literature and USA-based authors continue to dominate the most influential scientific literature in biomedicine, despite modest decline in the last decade. In contrast to previous work focused on publications in prestigious journals (4) or the top 1% of citations (5), where China apparently outpaced the USA, the current analysis shows that China still has negligible presence among the 100 most highly cited recent biomedical papers. NIH continues to be commonly listed as funder. Nevertheless, in recent papers, NIH is listed only about half that often compared with one or two decades ago. More prominently, in the recent cohort of extremely highly cited papers, NIH is almost never listed as the only funder, in stark contrast with just a decade ago.

Non-profit organizations, societies, and institutional support are increasingly listed as funders in top cited papers. Recent studies tend to have a wider range of acknowledged funders. Perhaps reporting of funders has become more detailed, on average, over time. Investigators may take more care to acknowledge support and/or journals may be more explicit in funding disclosures (14). Some institutional support is likely to have been and

continue to be common in all work from universities and research institutions. However, in the past this has typically not been acknowledged explicitly. Public funding may also have misclassification. Some investigators may not have listed their NIH funding, even if relevant to the work. Conversely, some other investigators may have listed NIH funding even if irrelevant to the published work. The latter pattern may become more frequent if investigators are increasingly pressured to demonstrate productivity to sponsors.

While other funders may cover some of the gap left by public research funding (15), public funding of the form provided by NIH is important to strengthen. Funding cuts may exacerbate pressure to game the system. The large majority of the first authors or even the corresponding authors (who may be more senior, on average) of the most recent USA-based extremely highly cited biomedical papers do not lead any currently active NIH grants. This is consistent with earlier analyses of NIH funding (16). More rather than less funding is therefore needed. Still, evidence-based efforts at research reform are welcome, including assessment of review, evaluation and funding distribution methods (17-19).

The top cited papers of 2023-4 show an increasing footprint of the pressure to boost impact metrics. The advent of massive publications has been associated with perverse incentives and even an increasing rate of fraud (20,21). This is particularly true for China (22,23). Outright fraud may be distinctly uncommon in the sample of extremely cited papers analyzed here, but gaming is likely. E.g., the share of consensus items has increased markedly compared with earlier periods. Guidelines and other consensus documents have seen major increases in production (24). Consensus documents can be very important, but the methodological rigor, and protection from conflicts for most of

them is questionable (25,26). Some journals have boosted their impact factors by engaging fervently in production of consensus documents. Another type of publication that achieves similar goals is the release of reference statistics. They can also be valuable, but they also provide routine citations for introduction sections. There is less methodological research on the validity of these exercises, but some early concerns have been raised even for the most rigorous among them (27).

The popularity of such papers may also lead to the publication of manuscripts that mimic their titles and thus share citation success. Authors usually do not read the papers they cite (28) and titles may mislead about the content. Another atypical situation documented here is the publication of a reporting guidance paper that is widely cited in articles appearing in the publishing journal. Finally, the considerable prevalence of reviews among the extremely cited publications is unsurprising. Reviews can attract many citations and often reflect the culmination or integration of important work and insightful syntheses. A worrisome pattern is the pervasive dearth of systematic approaches among extremely cited reviews. Several biases might have been curtailed with systematic methods (29,30). In some fields, especially in basic science, non-systematic reviews still draw a lot of attention, and they may be thought to provide a broader overview of the field. However, higher adoption of systematic review methods would improve also basic science (31).

Beyond highly cited articles, other indicators may be examined to obtain a comprehensive view of the evolution and current state of the research ecosystem in the USA, China, and globally. China has outpaced the USA not only in number of overall publications, but also in patent applications (1,619,268 versus 594,340 in 2023), patent

grants (798,347 versus 323,410 in 2023) (32), and new business applications (24.8 million

in the first 9 months of 2023 (33) versus 5.5 million in the entire 2023 (34), USA

publications have a higher rate of international collaboration than China (40% versus 22%

in 2023), but many other countries have even higher rates of international collaboration

than the USA (35). The decrease over time in the role of NIH is congruent with the decrease

in the proportion of R&D funding from government sources in the USA over time. In the

USA, government sources accounted for 20% of R&D in 2021 (latest available data, ref. 36

https://ncses.nsf.gov/pubs/nsb20246/cross-national-comparisons-of-r-d-performance),

while they represented 32% in 2010 (37) and 57% in the 1970s (38). In 2025, there have

been major threats for further sharp reductions in federal funding and increased

uncertainty. Conversely, the proportion of R&D with government source is higher in China

and the overall R&D expenditure in China was very close to that of the USA in 2021 and may

have fully matched the USA by now, if the long-term trends continued in the last 4 years

(39).

Some limitations should be acknowledged. First, citations are not equated with

disruptive innovation. However, it is difficult to measure disruption objectively, even more

so in recent work. There is some worrisome (40) but debated (41) evidence for substantial

recent decline in disruptiveness. Second, the citation potential of recently published

papers has not been fully expressed yet. Moreover, given the substantially longer time

available to be cited, papers published early in 2023 enjoy major advantages to reach the

top cited list than those published in late 2024. However, relative timing of publication

within 2023-4 is unlikely to be affected by country of provenance, type of paper or funding

pattern. There is no evidence that papers from a specific country, type, or funding are substantially more likely to start acquiring massive citations late, while relatively unnoticed early on (42). Such "sleeping beauties" are rather uncommon (42).

Acknowledging these caveats, the analyzed papers offer key referential landmarks for large, prolific and influential fields. This applies not only to traditional primary basic science research, but also to centralized resources, new methods, high-impact randomized trials, and even consensus statements, statistics, and reviews. In the current landscape, while the US remains a key player, its influence has diminished. The decrease is even more prominent for the presence of NIH funding and very prominent for solitary NIH funding. Strong public support of science is indispensable to ensure that research retains an orientation towards enhancing the public good. With threats for major cuts in government funding in 2025, it is important to avoid science becoming a political battlefield and secure bipartisan support for biomedical research.

References

1. Koshikawa N. China passes US as world's top researcher, showing its R&D might. https://asia.nikkei.com/Business/Science/China-passes-US-as-world-s-top-researcher-showing-its-R-D-might, last accessed March 1, 2025.

2. Hyland K. Enter the dragon: China and learned academic publishing. Learned Publishing 2023; 36: 394–403.

3. Enago Academy. China benefits enormously from the 33-fold increase in research expenditure. www.enago.com/academy/china-benefits-enormously-33-fold-increase-research-expenditure/, last accessed February 10, 2025.

4. Baker S. China overtakes United States on contribution to research in Nature Index. Nature. 2023 May 19. doi: 10.1038/d41586-023-01705-7.

5. Brainard J, Normile D. China rises to first place in one key metric of research impact. Science 2022;377(6608):799.

6. Graham F. Daily briefing: 'Devastating' cuts to NIH grants blocked by legal challenge. Nature. 2025 Feb 11. doi: 10.1038/d41586-025-00476-7.

7. Larivière V, Haustein S, Mongeon P. The Oligopoly of Academic Publishers in the Digital Era. PLoS ONE 2015;10(6): e0127502.

8. Ioannidis JPA, Thombs BD. A user's guide to inflated and manipulated impact factors. Eur J Clin Invest. 2019 Sep;49(9):e13151.

9. Ioannidis JPA. Professional Societies Should Abstain From Authorship of Guidelines and Disease Definition Statements. Circ Cardiovasc Qual Outcomes. 2018 Oct;11(10):e004889.

10. Ioannidis JPA, Maniadis Z. Quantitative research assessment: using metrics against gamed metrics. Intern Emerg Med. 2024 Jan;19(1):39-47.

11. Langin K. Researchers buy citations to inflate metrics. Science. 2024 Feb 23;383(6685):807.

12. NIH RePORTER, in https://reporter.nih.gov/, last accessed March 2, 2025.

13. Retraction Watch database, in https://retractiondatabase.org/RetractionSearch.aspx?, last accessed March 2, 2025.

14. Serghiou S, Contopoulos-Ioannidis DG, Boyack KW, Riedel N, Wallach JD, Ioannidis JPA. Assessment of transparency indicators across the biomedical literature: How open is open? PLoS Biol. 2021 Mar 1;19(3):e3001107.

15. National Center for Science and Engineering Statistics. Analysis of Federal Funding for Research and Development in 2022: Basic Research. In https://ncses.nsf.gov/pubs/nsf24332, last accessed March 2, 2025.

16. Nicholson JM, Ioannidis JP. Research grants: Conform and be funded. Nature. 2012 Dec 6;492(7427):34-6.

17. Schweiger G, Barnett A, van den Besselaar P, Bornmann L, De Block A, Ioannidis JPA, Sandström U, Conix S. The costs of competition in distributing scarce research funds. Proc Natl Acad Sci U S A. 2024 Dec 10;121(50):e2407644121.

18. Fang FC, Casadevall A. Research Funding: the Case for a Modified Lottery. mBio. 2016 Apr 12;7(2):e00422-16. doi: 10.1128/mBio.00422-16.

19. Moher D, Bouter L, Kleinert S, Glasziou P, Sham MH, Barbour V, Coriat AM, Foeger N, Dirnagl U. The Hong Kong Principles for assessing researchers: Fostering research integrity. PLoS Biol. 2020 Jul 16;18(7):e3000737.

20. Heathers J. How much science is fake? 2024 Sep 22 [cited 2025 Feb 18]; Available from: https://osf.io/5rf2m/.

21. Trueblood JS, Allison DB, Field SM, Fishbach A, Gaillard SDM, Gigerenzer G, et al. The misalignment of incentives in academic publishing and implications for journal reform. Proc Natl Acad Sci. 2025 Feb 4;122(5):e2401231121.

22. Quan W, Chen B, Shu F. Publish or impoverish: An investigation of the monetary reward system of science in China (1999-2016). Aslib Journal of Information Management 2017;69(5):486–502.

23. Xiao Y, Chen J, Wu X, Qiu QM. High retraction rate of Chinese articles: It is time to do something about academic misconduct. Postgraduate Medical Journal 2022;98: 653–654.

24. Mendlovic J, Mimouni FB, Arad I, Heiman E. Trends in Health Quality-Related Publications Over the Past Three Decades: Systematic Review. Interact J Med Res. 2022 Oct 4;11(2):e31055.

25. Lenzer J, Hoffman JR, Furberg CD, Ioannidis JP; Guideline Panel Review Working Group. Ensuring the integrity of clinical practice guidelines: a tool for protecting patients. BMJ. 2013 Sep 17;347:f5535.

26. Norris SL, Holmer HK, Ogden LA, Burda BU. Conflict of Interest in Clinical Practice Guideline Development: A Systematic Review. PLoS ONE 2011;6(10):e25153.

27. Polinder S, Haagsma JA, Stein C, Havelaar AH. Systematic review of general burden of disease studies using disability-adjusted life years. Population Health Metrics 2012;10: 21.

28. Simkin MV, Roychowdhury VP. Read before you cite!, arXiv preprint cond-mat/0212043, 2002.

29. Ioannidis JPA. Systematic reviews for basic scientists: a different beast. Physiol Rev. 2023 Jan 1;103(1):1-5.

30. Mulrow CD. The medical review article: state of the science. Ann Intern Med. 1987 Mar;106(3):485-8.

31. Ioannidis JPA. Systematic reviews for basic scientists: a different beast. Physiol Rev. 2023 Jan 1;103(1):1-5.

32. In: https://worldpopulationreview.com/country-rankings/patents-by-country, last accessed April 15, 2025.

33. In: https://english.www.gov.cn/archive/statistics/202311/07/content_WS6549f9dcc6d0 868f4e8e10c4.html) versus 5.5 million in the entire 2023, last accessed April 15, 2025.

34. In: https://www.uschamber.com/small-business/new-business-applications-a-state-by-state-view, last accessed April 15, 2025.

35. In: https://ncses.nsf.gov/pubs/nsb20214/international-collaboration-and-citations#:~:text=International%20collaboration%20rates%20vary%20by,(Figure%20PBS%2D4), last accessed April 15, 2025.

36. In: https://ncses.nsf.gov/pubs/nsb20246/cross-national-comparisons-of-r-d-performance, last accessed April 15, 2025.

37. In: https://files.eric.ed.gov/fulltext/ED615506.pdf, last accessed April 15, 2025.

38. Jaffe AB. Trends and patterns in research and development expenditures in the United States. Proc Natl Acad Sci U S A. 1996;93(23):12658-63.

39. In: https://ncses.nsf.gov/pubs/nsb20246/cross-national-comparisons-of-r-d-performance, last accessed April 15, 2025.

40. Park M, Leahey E, Funk RJ. Papers and patents are becoming less disruptive over time. Nature. 2023 Jan;613(7942):138-144.

41. Macher JT, Rutzer C, Weder R. Is there a secular decline in disruptive patents? Correcting for measurement bias. Research Policy 2024;53(5):104992.

42. Van Raan AFJ, Sleeping beauties in science. Scientometrics 2004;59(3):467-472.

Table 1. Top-5 countries with authors among all full papers (in parenthesis biomedical papers based on Scopus subject matter disciplines) published in 2003-4, 2013-4, and 2023-4 (per Scopus).

	2003-4	2013-4	2023-4
USA	832,986 (366,183)	1,134,424 (497,623)	1,251,053 (582,986)
Japan	224,808 (96,225)	253,129 (100,324)	255,483* (107,933*)
UK	212,575 (96,639)	323,403 (134,116)	412,215 (165,511)
Germany	202,425 (83,166)	311,383 (114,978)	367,622 (134,321)
China	197,638 (49,099*)	928,110 (208,047)	2,234,689 (606,424)
India	65,802* (24,407*)	233,392* (82,173*)	573,549 (152,891)

A total of 2,921,896 full papers were indexed in Scopus for 2003-2004, while 5,032,647 were indexed for 2013-4, and 7,550,657 were indexed for 2023-2024. Biomedical subject matter disciplines in Scopus include Medicine; Biochemistry, Genetics and Molecular Biology; Pharmacology, Toxicology and Pharmaceutics; Immunology and Microbiology; Neuroscience; Nursing; Health Professions; Veterinary; Dentistry. The total full papers in these subject matte Scopus categories were 1,181,567 in 2003-4, 1,812,401 in 2013-4, and 2,599,013 in 2023-4 (notably, additional papers in other disciplines may also have some high relevance for biomedicine and these are not counted in these numbers).

*not ranked among the top-5 countries

In 2003-4 biomedical papers, France was ranked 5th with 57,414 full papers, but was not among the top-5 in biomedical papers in any other time-period or in total full papers in any time period.

Table 2. Characteristics of the 100 most cited biomedical papers published in 2003-4, 2013-4, and 2023-4.

	Publication year for the most cited papers		
	2003-4	2013-4	2023-4
Range of citations	4983-48466	4403-53866	430-9785
Corresponding author in USA*	59	58	45
Other countries with corresponding	UK (8)	UK (10)	UK (16)
authors in >=4 papers	Germany (5)	Germany (8)	Germany (6)
	Canada (4)	France (5)	Spain (6)
			France (5)
			Italy (4)
			Switzerland (4)
			China (4)
Corresponding authors in non-high	0	3	10
Income countries			
Type of paper			
Primary research**	66	55	37
Resources and methods	34	30	17
Other	32	25	20
Reviews	23	20	28
Non-systematic	22	19	26
Systematic	1	1	2

Consensus items***	10	15	24
Reference statistics***	1	10	11

*A few society-based papers did not list explicitly corresponding authors but were then allocated to the country of the society (unless the society was not based in a single country).

**Some methodological papers are difficult to classify in the subgroup "Resources and methods" versus "Other"; only one of the two was chosen to avoid double-counting.

***Consensus items and reference statistics may sometimes also use review methods (including systematic review methods), but they are not classified as Reviews, so as to keep the categories of types of paper mutually exclusive.

Table 3. Funding of the 100 most cited biomedical papers published in 2003-4, 2013-4, and 2023-4

	Publication year for the most cited papers		
	2003-4	2013-4	2023-4
NIH	45	50	23
Other US federal/public	4	9	4
Other country public/government*	29	43	37
Non-profit	13	21	24
For-profit	14	8	22
Societies**	6	9	25
Institutional	4	11	18
None listed	21	7	16

The sum for each cohort exceeds 100, because some papers listed more than one categories of funding.

*includes international government-funded organizations such as International Agency for Research on Cancer (IARC), World Health Organization (WHO), and United Nations (UN).

**when a paper was generated by one or more societies, these were considered to have funded the effort, even if funding was not explicitly listed.

Table 4. Co-existence of other funders in the NIH-funded top cited papers

	Publication year for the most cited papers		
	2003-4	2013-4	2023-4
	(n=45)	(n=50)	(n=23)
By presence of other funders			
NIH alone	32	28	2
NIH and other listed funders	13	22	21
By type of other funders			
Other US federal/public	2	7	3
Other country public/government*	3	16	8
Non-profit	8	11	13
For-profit	4	5	7
Societies**	2	3	2
Institutional	2	4	7

*includes international government-funded organizations such as IARC, WHO, and UN

**when a paper was generated by one or more societies, these were considered to have funded the effort, even if funding was not explicitly listed.

SUPPLEMENTARY TABLES

Supplementary Table 1. 100 top cited biomedical papers published in 2003-4

Title	Type of paper	Year	Source	Cited	Country	Classified funding
Measuring inconsistency in meta-analyses	Resource	2003	BMJ	48466	UK	UK
MUSCLE: Multiple sequence alignment with high accuracy and high throughput	Resource	2004	Nucleic Acids Research	35453	USA	European
UCSF Chimera - A visualization system for exploratory research and analysis	Resource	2004	Journal of Computational Chemistry	34953	USA	NIH
Cytoscape: A software Environment for integrated models of biomolecular interaction networks	Resource	2003	Genome Research	34551	USA	NIH
MicroRNAs: Genomics, Biogenesis, Mechanism, and Function	Resource	2004	Cell	31906	USA	NIH/non-profit
MrBayes 3: Bayesian phylogenetic inference under mixed models	Resource	2003	Bioinformatics	27150	Sweden	NSF/Sweden
Coot: Model-building tools for molecular graphics	Resource	2004	Acta Crystallographica Section D	25964	UK	UK/societies
Classification of surgical complications: A new proposal with evaluation in a cohort of 6336 patients and results of a survey	Resource	2004	Annals of Surgery	25433	Switzerland	None
EEGLAB: An open source toolbox for analysis of single-trial EEG dynamics including independent component analysis	Resource	2004	Journal of Neuroscience Methods	17538	USA	NIH/non-profit/institution
The seventh report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure: The JNC 7 report	Consensus	2003	JAMA	17348	USA	NIH
International physical activity questionnaire: 12-Country reliability and validity	Resource	2003	Medicine and Science in Sports and Exercise	15013	Australia	None

Development and testing of a general Amber force field	Resource	2004	Journal of Computational Chemistry	14870	USA	NIH
Qualitative content analysis in nursing research: Concepts, procedures and measures to achieve trustworthiness	Resource	2004	Nurse Education Today	13264	Sweden	None
Global Prevalence of Diabetes: Estimates for the year 2000 and projections for 2030	Reference statistics	2004	Diabetes Care	12676	UK	None
Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure	Consensus	2003	Hypertension	11236	USA	NIH
Mfold web server for nucleic acid folding and hybridization prediction	Resource	2003	Nucleic Acids Research	11185	USA	NIH
MEGA3: Integrated software for Molecular Evolutionary Genetics Analysis and sequence alignment.	Resource	2004	Briefings in bioinformatics	10724	USA	NIH/NSF/non-profit
Advances in functional and structural MR image analysis and implementation as FSL	Resource	2004	NeuroImage	10689	UK	UK/for-profit/non-profit
Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non-Small-Cell Lung Cancer to Gefitinib	Article	2004	NEJM	10509	USA	NIH
Prejudice, Social Stress, and Mental Health in Lesbian, Gay, and Bisexual Populations: Conceptual Issues and Research Evidence	Article	2003	Psychological Bulletin	10327	USA	NIH
Bioconductor: open software development for computational biology and bioinformatics.	Resource	2004	Genome biology	9996	USA	None
Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization	Article	2004	NEJM	9949	USA	NIH
The functions of animal microRNAs	Review	2004	Nature	9717	USA	NIH
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer	Article	2004	NEJM	9669	USA	NIH
Linear models and empirical bayes methods for assessing differential expression in microarray experiments	Resource	2004	Statistical Applications in Genetics and	9650	Australia	Australia

			Molecular Biology			
WebLogo: A sequence logo generator	Resource	2004	Genome Research	9649	USA	NIH
Appropriate body-mass index for Asian populations and its implications for policy and intervention strategies	Article	2004	Lancet	9541	Switzerland	Japan/Singapore
Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): Case-control study	Article	2004	Lancet	9454	Canada	Canada/for-profit/non-profit
APE: Analyses of phylogenetics and evolution in R language	Resource	2004	Bioinformatics	9296	France	Germany
Prospective identification of tumorigenic breast cancer cells	Article	2003	PNAS	8961	USA	NIH
EGFR mutations in lung, cancer: Correlation with clinical response to gefitinib therapy	Article	2004	Science	8893	USA	NIH
Exploration, normalization, and summaries of high density oligonucleotide array probe level data.	Resource	2003	Biostatistics	8770	USA	NIH
The Benefits of Being Present: Mindfulness and Its Role in Psychological Well-Being	Review	2003	Journal of Personality and Social Psychology	8530	USA	NIH/societies/non-profit/Canada
Essential oils: Their antibacterial properties and potential applications in foods - A review	Review	2004	International Journal of Food Microbiology	8444	Netherlands	None
The biology of VEGF and its receptors	Review	2003	Nature Medicine	8424	USA	None
Staging of brain pathology related to sporadic Parkinson's disease	Article	2003	Neurobiology of Aging	8338	Germany	Germany/Australia
Obesity is associated with macrophage accumulation in adipose tissue	Article	2003	Journal of Clinical Investigation	8216	USA	NIH
The International Classification of Headache Disorders: 2nd edition.	Consensus	2004	Cephalalgia	8168	Denmark	None

DAVID: Database for Annotation, Visualization, and Integrated Discovery.	Resource	2003	Genome biology	8052	USA	NIH
Individual Differences in Two Emotion Regulation Processes: Implications for Affect, Relationships, and Well-Being	Article	2003	Journal of Personality and Social Psychology	7851	USA	NIH
Glide: A New Approach for Rapid, Accurate Docking and Scoring. 1. Method and Assessment of Docking Accuracy	Resource	2004	Journal of Medicinal Chemistry	7775	USA	NIH
Neutrophil Extracellular Traps Kill Bacteria	Article	2004	Science	7735	Germany	NIH
Statistical significance for genomewide studies	Article	2003	PNAS	7684	USA	None
PGC-1α-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes	Article	2003	Nature Genetics	7474	USA	HHMI/non-profit/for-profit/Sweden
A Modified Poisson Regression Approach to Prospective Studies with Binary Data	Resource	2004	American Journal of Epidemiology	7234	Canada	Canada
Control of regulatory T cell development by the transcription factor Foxp3	Article	2003	Science	7173	Japan	Japan
Toll-like receptor signalling	Review	2004	Nature Reviews Immunology	7155	Japan	Japan/non-profit
Development of a new Resilience scale: The Connor-Davidson Resilience scale (CD-RISC)	Resource	2003	Depression and Anxiety	7048	USA	NIH/for-profit
MUSCLE: A multiple sequence alignment method with reduced time and space complexity	Resource	2004	BMC Bioinformatics	6960	USA	Japan
The Epidemiology of Major Depressive Disorder: Results from the National Comorbidity Survey Replication (NCS-R)	Article	2003	JAMA	6817	USA	NIH
Inference of population structure using multilocus genotype data: Linked loci and correlated allele frequencies	Article	2003	Genetics	6812	Germany	NIH
A comparison of normalization methods for high density oligonucleotide array data based on variance and bias	Resource	2003	Bioinformatics	6728	USA	None

Influence of life stress on depression: Moderation by a polymorphism in the 5-HTT gene	Article	2003	Science	6536	UK	NIH
Foxp3 programs the development and function of CD4+CD25+ regulatory T cells	Article	2003	Nature Immunology	6509	USA	NIH/HHMI/non-profit
Polyphenols: Food sources and bioavailability	Review	2004	American Journal of Clinical Nutrition	6503	France	None
Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. Adults	Article	2003	NEJM	6472	USA	None
Identification of human brain tumour initiating cells	Article	2004	Nature	6462	Canada	Canada/non-profit/institution
Mild cognitive impairment as a diagnostic entity	Review	2004	Journal of Internal Medicine	6296	USA	NIH
Network biology: Understanding the cell's functional organization	Review	2004	Nature Reviews Genetics	6269	USA	NIH/NSF/DOE
The fourth report on the diagnosis, evaluation, and treatment of high blood pressure in children and adolescents	Consensus	2004	Pediatrics	6202	USA	NIH
Multidimensional Assessment of Emotion Regulation and Dysregulation: Development, Factor Structure, and Initial Validation of the Difficulties in Emotion Regulation Scale	Resource	2004	Journal of Psychopathology and Behavioral Assessment	6099	USA	Institution
MicroRNAs: Small RNAs with a big role in gene regulation	Review	2004	Nature Reviews Genetics	6068	USA	NIH
The mirror-neuron system	Review	2004	Annual Review of Neuroscience	6045	Italy	None
Confidence limits for the indirect effect: Distribution of the product and resampling methods	Resource	2004	Multivariate Behavioral Research	6012	USA	NIH
Normalization of real-time quantitative reverse transcription-PCR data: A model-based variance estimation approach to identify genes suited for	Article	2004	Cancer Research	5955	Denmark	European

normalization, applied to bladder and colon cancer data sets						
Mass spectrometry-based proteomics	Review	2003	Nature	5925	USA	NIH/for-profit/Denmark
Photodynamic therapy for cancer	Review	2003	Nature Reviews Cancer	5914	USA	NIH/non-profit
Bariatric surgery: A systematic review and meta-analysis	Review	2004	JAMA	5849	USA	For-profit
Targeting HIF-1 for cancer therapy	Review	2003	Nature Reviews Cancer	5789	USA	None
Improved prediction of signal peptides: SignalP 3.0	Resource	2004	Journal of Molecular Biology	5767	Denmark	Denmark/for-profit
Acute renal failure - definition, outcome measures, animal models, fluid therapy and information technology needs: the Second International Consensus Conference of the Acute Dialysis Quality Initiative (ADQI) Group.	Consensus	2004	Critical care (London, England)	5694	Australia	None
Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance	Article	2003	Journal of Clinical Investigation	5600	USA	None
Markers of inflammation and cardiovascular disease: Application to clinical and public health practice: A statement for healthcare professionals from the centers for disease control and prevention and the American Heart Association	Consensus	2003	Circulation	5586	USA	CDC/For-profit
Bacterial biofilms: From the natural environment to infectious diseases	Review	2004	Nature Reviews Microbiology	5585	USA	NIH
Methodological index for non-randomized studies (Minors): Development and validation of a new instrument	Resource	2003	ANZ Journal of Surgery	5548	France	None
Osteoclast differentiation and activation	Review	2003	Nature	5522	USA	None
DnaSP, DNA polymorphism analyses by the coalescent and other methods	Resource	2003	Bioinformatics	5457	Spain	Spain

ARB: A software environment for sequence data	Resource	2004	Nucleic Acids Research	5455	Germany	Germany
Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome	Consensus	2004	Fertility and Sterility	5445	Netherland	For-profit/societies
Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome	Consensus	2004	Human Reproduction	5398	Netherlands	For-profit/societies
Silver nanoparticles as antimicrobial agent: A case study on E. coli as a model for Gram-negative bacteria	Article	2004	Journal of Colloid and Interface Science	5352	Croatia	Croatia
Functional connectivity in the resting brain: A network analysis of the default mode hypothesis	Article	2003	PNAS	5325	USA	NIH
Epidemiologic classification of human papillomavirus types associated with cervical cancer	Article	2003	NEJM	5297	Spain	Spain
Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer	Article	2004	NEJM	5269	Canada	For-profit
A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer	Article	2004	NeEJM	5252	USA	NIH/for-profit
Preoperative versus postoperative chemoradiotherapy for rectal cancer	Article	2004	NEJM	5249	Germany	Germany
Mindfulness-based interventions in context: Past, present, and future	Review	2003	Clinical Psychology: Science and Practice	5210	USA	None
Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines	Consensus	2004	Circulation	5198	USA	NIH/societies
The international HapMap project	Resource	2003	Nature	5184	UK	NIH/non-profit/for-profit/international/institutional
The chemokine system in diverse forms of macrophage activation and polarization	Review	2004	Trends in Immunology	5175	Italy	Italy

Title	Type of paper	Year	Source title	Cited	Country	Funding
Mechanisms of TGF-β signaling from cell membrane to the nucleus	Review	2003	Cell	5153	USA	NIH/HHMI
Brown Adipose Tissue: Function and Physiological Significance	Review	2004	Physiological Reviews	5152	Sweden	Sweden
The epidemiology of sepsis in the United States from 1979 through 2000	Article	2003	NEJM	5131	USA	NIH
Alternative activation of macrophages	Review	2003	Nature Reviews Immunology	5121	UK	UK/non-profit
Cardiac-Resynchronization Therapy with or without an Implantable Defibrillator in Advanced Chronic Heart Failure	Article	2004	NEJM	5104	USA	For-profit
Epigenetic regulation of gene expression: How the genome integrates intrinsic and environmental signals	Review	2003	Nature Genetics	5062	USA	None
The gut microbiota as an environmental factor that regulates fat storage	Article	2004	PNAS	5048	USA	NIH
Hazards of heavy metal contamination	Review	2003	British Medical Bulletin	5037	UK	None
2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference	Consensus	2003	Critical Care Medicine	5008	USA	Societies
SIFT: Predicting amino acid changes that affect protein function	Resource	2003	Nucleic Acids Research	4983	USA	NIH

Supplementary Table 2. 100 cited biomedical papers published in 2013-4

Title	Type of paper	Year	Source title	Cited	Country	Funding
Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2	Resource	2014	Genome Biology	53866	Germany	NIH/European/institution
Trimmomatic: A flexible trimmer for Illumina sequence data	Resource	2014	Bioinformatics	41694	Germany	Germany
MEGA6: Molecular evolutionary genetics analysis version 6.0	Resource	2013	Molecular Biology and Evolution	36548	USA	NIH/Japan

MAFFT multiple sequence alignment software version 7: Improvements in performance and usability	Resource	2013	Molecular Biology and Evolution	30829	Japan	Japan
STAR: Ultrafast universal RNA-seq aligner	Resource	2013	Bioinformatics	29530	USA	NIH
RAxML version 8: A tool for phylogenetic analysis and post-analysis of large phylogenies	Resource	2014	Bioinformatics	24870	Germany	Institution
The SILVA ribosomal RNA gene database project: Improved data processing and web-based tools	Resource	2013	Nucleic Acids Research	21199	Germany	Germany
FeatureCounts: An efficient general purpose program for assigning sequence reads to genomic features	Resource	2014	Bioinformatics	14943	USA	Australia
Investigation of the freely available easy-to-use software 'EZR' for medical statistics	Resource	2013	Bone Marrow Transplantation	13173	Japan	None listed
UPARSE: Highly accurate OTU sequences from microbial amplicon reads	Resource	2013	Nature Methods	12968	USA	Non-profit/institution
Phyloseq: An R Package for Reproducible Interactive Analysis and Graphics of Microbiome Census Data	Resource	2013	PLoS ONE	12749	USA	NIH
Multiplex genome engineering using CRISPR/Cas systems	Article	2013	Science	12157	USA	NIH
Cancer statistics, 2013	Reference statistics	2013	CA Cancer	11912	USA	Societies
Cancer statistics, 2014	Reference statistics	2014	CA Cancer	11514	USA	Societies
Prokka: Rapid prokaryotic genome annotation	Resource	2014	Bioinformatics	11508	Australia	Institution
Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal	Resource	2013	Science Signaling	11145	USA	NIH
The hallmarks of aging	Review	2013	Cell	10740	Spain	Multiple international/non-profit/for-profit
TopHat2: Accurate alignment of transcriptomes in the presence of insertions, deletions and gene fusions	Resource	2013	Genome Biology	9853	USA	NIH
Global, regional, and national prevalence of overweight and obesity in children and adults during 1980-2013: A systematic analysis for the Global Burden of Disease Study 2013	Reference statistics	2014	Lancet	9318	USA	NIH/for-profit/non-profit/international

Executive functions	Review	2013	Annual Review of Psychology	8721	Canada	NIH
GSVA: Gene set variation analysis for microarray and RNA-Seq data	Resource	2013	BMC Bioinformatics	8442	Spain	NIH/Spain
Genome engineering using the CRISPR-Cas9 system	Article	2013	Nature Protocols	8184	USA	NIH/non-profit
RNA-guided human genome engineering via Cas9	Article	2013	Science	7500	USA	NIH
Signatures of mutational processes in human cancer	Article	2013	Nature	7461	UK	NIH/European
Random effects structure for confirmatory hypothesis testing: Keep it maximal	Article	2013	Journal of Memory and Language	7436	UK	NIH/UK
Diet rapidly and reproducibly alters the human gut microbiome	Article	2014	Nature	7344	USA	NIH
NCBI GEO: Archive for functional genomics data sets – Update	Resource	2013	Nucleic Acids Research	7202	USA	NIH
Predictive functional profiling of microbial communities using 16S rRNA marker gene sequences	Article	2013	Nature Biotechnology	7186	USA	NIH/NSF/ARO/non-profit/Canada
The global distribution and burden of dengue	Reference statistics	2013	Nature	7062	UK	NIH/DHS/non-profit/European
Estimating the sample mean and standard deviation from the sample size, median, range and/or interquartile range	Resource	2014	BMC Medical Research Methodology	6971	Hong Kong	Hong Kong/institution
The strengthening the reporting of observational studies in epidemiology (STROBE) statement: Guidelines for reporting observational studies	Consensus	2014	International Journal of Surgery	6842	Switzerland	European
Prevalence of childhood and adult obesity in the United States, 2011-2012	Reference statistics	2014	JAMA	6701	USA	CDC
Expert consensus document: The international scientific association for probiotics and prebiotics consensus statement on the scope and appropriate use of the term probiotic	Consensus	2014	Nature Reviews Gastroenterology and Hepatology	6695	USA	Societies
2014 Evidence-based guideline for the management of high blood pressure in adults: Report from the panel members appointed to the Eighth Joint National Committee (JNC 8)	Consensus	2014	JAMA	6601	USA	NIH

Frailty in elderly people	Review	2013	Lancet	6553	UK	None listed
Molecular mechanisms of epithelial-mesenchymal transition	Review	2014	Nature Reviews Molecular Cell Biology	6501	USA	NIH
Natural RNA circles function as efficient microRNA sponges	Article	2013	Nature	6496	Denmark	Denmark/non-profit
Standards for reporting qualitative research: A synthesis of recommendations	Consensus	2014	Academic Medicine	6490	USA	None listed
Using the framework method for the analysis of qualitative data in multi-disciplinary health research	Resource	2013	BMC Medical Research Methodology	6488	UK	UK
Circular RNAs are a large class of animal RNAs with regulatory potency	Article	2013	Nature	6481	Germany	Germany/institution
QUAST: Quality assessment tool for genome assemblies	Resource	2013	Bioinformatics	6456	Russia	NIH
Extracellular vesicles: Exosomes, microvesicles, and friends	Review	2013	Journal of Cell Biology	6455	France	France/for-profit/institution
Better reporting of interventions: Template for intervention description and replication (TIDieR) checklist and guide	Consensus	2014	BMJ	6214	Australia	UK/Australia/non-profit
The International Classification of Headache Disorders, 3rd edition (beta version)	Consensus	2013	Cephalalgia	6190	USA	NIH/societies/for-profit/institution/Canada
Integrative Genomics Viewer (IGV): High-performance genomics data visualization and exploration	Resource	2013	Briefings in Bioinformatics	6170	USA	NIH
Evaluation of general 16S ribosomal RNA gene PCR primers for classical and next-generation sequencing-based diversity studies	Article	2013	Nucleic Acids Research	6068	Germany	Germany/Austria/European
Inferring tumour purity and stromal and immune cell admixture from expression data	Article	2013	Nature Communications	6055	USA	NIH
GROMACS 4.5: A high-throughput and highly parallel open source molecular simulation toolkit	Resource	2013	Bioinformatics	6052	Sweden	NIH/European/Sweden

De novo transcript sequence reconstruction from RNA-seq using the Trinity platform for reference generation and analysis	Resource	2013	Nature Protocols	6018	USA	NIH/NSF/non-profit/for-profit/international
Cancer genome landscapes	Review	2013	Science	6010	USA	NIH
Pilon: An integrated tool for comprehensive microbial variant detection and genome assembly improvement	Resource	2014	PLoS ONE	6001	USA	NIH
Microenvironmental regulation of tumor progression and metastasis	Review	2013	Nature Medicine	5957	USA	NIH/societies/non-profit/Canada
Biological insights from 108 schizophrenia-associated genetic loci	Article	2014	Nature	5906	UK	NIH/VA/UK/European
The cancer genome atlas pan-cancer analysis project	Resource	2013	Nature Genetics	5771	USA	NIH
InterProScan 5: Genome-scale protein function classification	Resource	2014	Bioinformatics	5554	UK	European
Projecting cancer incidence and deaths to 2030: The unexpected burden of thyroid, liver, and pancreas cancers in the united states	Reference statistics	2014	Cancer Research	5482	USA	Non-profit
3D bioprinting of tissues and organs	Review	2014	Nature Biotechnology	5441	USA	None listed
Content analysis and thematic analysis: Implications for conducting a qualitative descriptive study	Review	2013	Nursing and Health Sciences	5418	Finland	Institution
PD-1 blockade induces responses by inhibiting adaptive immune resistance	Article	2014	Nature	5384	USA	NIH/HHMI/for-profit/non-profit/societies
2013 ACCF/AHA guideline for the management of heart failure: A report of the American college of cardiology foundation/american heart association task force on practice guidelines	Consensus	2013	Journal of the American College of Cardiology	5380	USA	Societies
Maternal and child undernutrition and overweight in low-income and middle-income countries	Review	2013	Lancet	5374	USA	Non-profit
A 3D map of the human genome at kilobase resolution reveals principles of chromatin looping	Article	2014	Cell	5346	USA	NIH/NSF/non-profit/institution
Angiotensin-neprilysin inhibition versus enalapril in heart failure	Article	2014	NEJM	5325	USA/UK	For-profit
Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine	Article	2013	NEJM	5254	USA	NIH

Genome sequence-based species delimitation with confidence intervals and improved distance functions	Article	2013	BMC Bioinformatics	5249	Germany	Germany/Spain
Development of a dual-index sequencing strategy and curation pipeline for analyzing amplicon sequence data on the miseq illumina sequencing platform	Resource	2013	Applied and Environmental Microbiology	5161	USA	NIH
2012 Revised International Chapel Hill consensus conference nomenclature of vasculitides	Consensus	2013	Arthritis and Rheumatism	5161	USA	None listed
Regulation of ferroptotic cancer cell death by GPX4	Article	2014	Cell	5127	USA	NIH
Power failure: Why small sample size undermines the reliability of neuroscience	Article	2013	Nature Reviews Neuroscience	5098	UK	UK
Global prevalence of glaucoma and projections of glaucoma burden through 2040: A systematic review and meta-analysis	Reference statistics	2014	Ophthalmology	5070	Singapore	Singapore
Oncology meets immunology: The cancer-immunity cycle	Review	2013	Immunity	5060	USA	None listed
ROS function in redox signaling and oxidative stress	Review	2014	Current Biology	5059	USA	NIH
BEAST 2: A Software Platform for Bayesian Evolutionary Analysis	Resource	2014	PLoS Computational Biology	5032	New Zealand	NIH
Classification of acute pancreatitis - 2012: Revision of the Atlanta classification and definitions by international consensus	Consensus	2013	Gut	4963	USA	Societies
Comprehensive molecular characterization of gastric adenocarcinoma	Article	2014	Nature	4953	USA	NIH
Deciphering key features in protein structures with the new ENDscript server	Resource	2014	Nucleic Acids Research	4933	France	France
The carbohydrate-active enzymes database (CAZy) in 2013	Resource	2014	Nucleic Acids Research	4892	France	France
The behavior change technique taxonomy (v1) of 93 hierarchically clustered techniques: Building an international consensus for the reporting of behavior change interventions	Consensus	2013	Annals of Behavioral Medicine	4862	UK	UK
Biogenesis, secretion, and intercellular interactions of exosomes and other extracellular vesicles	Review	2014	Annual Review of Cell and	4848	France	France/non-profit

			Developmental Biology			
Pfam: The protein families database	Review	2014	Nucleic Acids Research	4846	USA	HHMI/European/non-profit
Surviving sepsis campaign: International guidelines for management of severe sepsis and septic shock: 2012	Consensus	2013	Critical Care Medicine	4840	USA	Non-profit
Heart Disease and Stroke Statistics - 2014 Update: A report from the American Heart Association	Review	2014	Circulation	4810	USA	NIH
The new frontier of genome engineering with CRISPR-Cas9	Review	2014	Science	4775	USA/Germany	NIH/NSF/non-profit
Analysis of the structural diversity, substitution patterns, and frequency of nitrogen heterocycles among U.S. FDA approved pharmaceuticals	Article	2014	Journal of Medicinal Chemistry	4603	USA	NSF
Enrichr: Interactive and collaborative HTML5 gene list enrichment analysis tool	Resource	2013	BMC Bioinformatics	4601	USA	NIH
From fastQ data to high-confidence variant calls: The genome analysis toolkit best practices pipeline	Consensus	2013	Current Protocols in Bioinformatics	4600	USA	NIH
Macrophage Activation and Polarization: Nomenclature and Experimental Guidelines	Consensus	2014	Immunity	4574	USA	NIH/UK/European/non-profit
Heart disease and stroke statistics-2013 update: A Report from the American Heart Association	Reference statistics	2013	Circulation	4572	USA	NIH
Diagnosis and classification of diabetes mellitus	Consensus	2014	Diabetes Care	4568	USA	Societies
Toxicity, mechanism and health effects of some heavy metals	Review	2014	Interdisciplinary Toxicology	4563	India	None listed
SPIRIT 2013 statement: Defining standard protocol items for clinical trials	Consensus	2013	Annals of Internal Medicine	4545	Canada	Canada
Global burden of disease attributable to mental and substance use disorders: Findings from the Global Burden of Disease Study 2010	Reference statistics	2013	Lancet	4534	Australia	NIH/Australia
Ultrasensitive fluorescent proteins for imaging neuronal activity	Article	2013	Nature	4512	USA	NIH/Switzerland/European

A general framework for estimating the relative pathogenicity of human genetic variants	Article	2014	Nature Genetics	4510	USA	NIH
Regulation of microRNA biogenesis	Review	2014	Nature Reviews Molecular Cell Biology	4458	Korea	Korea
Ultrasensitive photodetectors based on monolayer MoS 2	Article	2013	Nature Nanotechnology	4446	Switzerland	Switzerland/European
Chimeric antigen receptor T cells for sustained remissions in leukemia	Article	2014	NEJM	4414	USA	NIH/for-profit/non-profit/institution
Development and applications of CRISPR-Cas9 for genome engineering	Review	2014	Cell	4403	USA	NIH/NSF/non-profit
Cancer incidence and mortality patterns in Europe: Estimates for 40 countries in 2012	Reference statistics	2013	European Journal of Cancer	4381	France	European/IARC
Lipid peroxidation: Production, metabolism, and signaling mechanisms of malondialdehyde and 4-hydroxy-2-nonenal	Review	2014	Oxidative Medicine and Cellular Longevity	4376	Spain	Spain

Supplementary Table 3. 100 top cited biomedical papers published in 2023-4

Title	Type of paper	Year	Source title	Cited	Country	Funding
Cancer statistics, 2023	Reference statistics	2023	CA Cancer	9785	USA	Societies
Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries	Reference statistics	2024	CA Cancer	3306	France	IARC+WHO
Cancer statistics, 2024	Reference statistics	2024	CA Cancer	2543	USA	Societies
UniProt: the Universal Protein Knowledgebase in 2023	Resources	2023	Nucleic Acids Research	2494	UK	NIH/UK/Germany/European
KEGG for taxonomy-based analysis of pathways and genomes	Resources	2023	Nucleic Acids Research	2282	Japan	None

Heart Disease and Stroke Statistics - 2023 Update: A Report from the American Heart Association	Reference statistics	2023	Circulation	2199	USA	NIH/societies
The STRING database in 2023: protein-protein association networks and functional enrichment analyses for any sequenced genome of interest	Resources	2023	Nucleic Acids Research	2130	Switzerland/Denmark/ Germany	Multiple international/for-profit
Lecanemab in Early Alzheimer's Disease	Article	2023	NEJM	2101	USA	For-profit
Long COVID: major findings, mechanisms and recommendations	Review	2023	Nature Reviews Microbiology	1889	USA	NIH
Hallmarks of aging: An expanding universe	Review	2023	Cell	1810	Spain/France	For-profit/non-profit/international/institution
Performance of ChatGPT on USMLE: Potential for AI-assisted medical education using large language models	Article	2023	PLOS Digital Health	1607	USA	None
The SCARE 2023 guideline: updating consensus Surgical CAse REport (SCARE) guidelines	Consensus	2023	International journal of surgery	1593	UK	None
FinnGen provides genetic insights from a well-phenotyped isolated population	Article	2023	Nature	1424	Finland	Finland
2023 Alzheimer's disease facts and figures	Review	2023	Alzheimer's and Dementia	1372	USA	CDC/non-profit/institution
Swin-Unet: Unet-Like Pure Transformer for Medical Image Segmentation	Resources	2023	Lecture Notes in Artificial Intelligence and Lecture Notes in Bioinformatics)	1364	China	None

2023 ESC Guidelines for the management of acute coronary syndromes	Consensus	2023	European Heart Journal	1348	Ireland/Spain	Societies
PubChem 2023 update	Resources	2023	Nucleic Acids Research	1298	USA	NIH
Colorectal cancer statistics, 2023	Reference statistics	2023	CA Cancer	1213	USA	Societies
2023 ESH Guidelines for the management of arterial hypertension the Task Force for the management of arterial hypertension of the European Society of Hypertension: Endorsed by the International Society of Hypertension (ISH) and the European Renal Association (ERA)	Consensus	2023	Journal of Hypertension	1207	Italy/Germany	Societies
Global, regional, and national burden of diabetes from 1990 to 2021, with projections of prevalence to 2050: a systematic analysis for the Global Burden of Disease Study 2021	Reference statistics	2023	Lancet	1206	USA	NIH/non-profit/multiple international
ChatGPT Utility in Healthcare Education, Research, and Practice: Systematic Review on the Promising Perspectives and Valid Concerns	Review	2023	Healthcare (Switzerland)	1189	Jordan	None
Covid-19 pandemic and online learning: the challenges and opportunities	Review	2023	Interactive Learning Environments	1181	Cyprus	None
Accurate structure prediction of biomolecular interactions with AlphaFold 3	Resources	2024	Nature	1146	UK	For-profit

A multisociety Delphi consensus statement on new fatty liver disease nomenclature	Consensus	2023	Journal of Hepatology	1117	USA	European/societies
2. Classification and Diagnosis of Diabetes: Standards of Care in Diabetes—2023	Consensus	2023	Diabetes Care	1113	USA	Societies
InterPro in 2022	Resources	2023	Nucleic Acids Research	1112	UK	NIH/NSF/non-profit/multiple international
Empagliflozin in Patients with Chronic Kidney Disease	Article	2023	New England Journal of Medicine	1104	UK	Non-profit/for-profit/UK/Japan
Evolutionary-scale prediction of atomic-level protein structure with a language model	Article	2023	Science	1095	USA	Non-profit/for-profit/UK/Japan
The evolving tumor microenvironment: From cancer initiation to metastatic outgrowth	Review	2023	Cancer Cell	997	Netherlands/Switzerland	For-profit/non-profit/international/institution
A multisociety Delphi consensus statement on new fatty liver disease nomenclature	Consensus	2023	Hepatology	957	USA/UK	None
Prevalence and Characteristics of Autism Spectrum Disorder Among Children Aged 8 Years — Autism and Developmental Disabilities Monitoring Network, 11 Sites, United States, 2020	Article	2023	MMWR Surveillance Summaries	953	USA	None
The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review	Review	2023	Hepatology	947	USA	For-profit
How Does ChatGPT Perform on the United States Medical Licensing Examination? The Implications of	Article	2023	JMIR Medical Education	929	USA	NIH/institution

Large Language Models for Medical Education and Knowledge Assessment						
Large language models in medicine	Review	2023	Nature Medicine	887	Singapore	Singapore/international
AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease	Consensus	2023	Hepatology	857	USA	Societies
Comparing Physician and Artificial Intelligence Chatbot Responses to Patient Questions Posted to a Public Social Media Forum	Article	2023	JAMA Internal Medicine	852	USA	NIH/non-profit
2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension	Consensus	2023	European Respiratory Journal	793	Germany/Belgium	Societies
TBtools-II: A "one for all, all for one" bioinformatics platform for biological big-data mining	Resources	2023	Molecular Plant	789	China	China
Large language models encode clinical knowledge	Article	2023	Nature	784	USA	For-profit
Donanemab in Early Symptomatic Alzheimer Disease: The TRAILBLAZER-ALZ 2 Randomized Clinical Trial	Article	2023	JAMA	757	USA	NIH/for-profit/societies
Long non-coding RNAs: definitions, functions, challenges and recommendations	Review	2023	Nature Reviews Molecular Cell Biology	747	Australia	Japan
The IPD-IMGT/HLA Database	Resources	2023	Nucleic Acids Research	737	UK	Societies/for-profit/non-profit/institution
Benefits, Limits, and Risks of GPT-4 as an AI Chatbot for Medicine.	Review	2023	NEJM	732	USA	For-profit

Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes	Article	2023	NEJM	719	USA	For-profit
AntiSMASH 7.0: New and improved predictions for detection, regulation, chemical structures and visualisation	Resources	2023	Nucleic Acids Research	719	Denmark/Netherlands	For-profit/multiple international
The Gene Ontology knowledgebase in 2023	Resources	2023	Genetics	719	USA	NIH/NSF/DOE/non-profit/multiple European
2023 Focused Update of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure Developed by the task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) With the special contribution of the Heart Failure Association (HFA) of the ESC	Consensus	2023	European Heart Journal	715	UK/Italy	Societies
2023 ESC Guidelines for the management of cardiomyopathies: Developed by the task force on the management of cardiomyopathies of the European Society of Cardiology (ESC)	Consensus	2023	European Heart Journal	713	Spain/UK	Societies
Minimal information for studies of extracellular vesicles (MISEV2023): From basic to advanced approaches	Consensus	2024	Journal of Extracellular Vesicles	712	USA/France/Ireland/UK	None
Global burden of colorectal cancer in 2020 and 2040: Incidence and mortality estimates from GLOBOCAN	Reference statistics	2023	Gut	708	France	IARC
Metastatic colorectal cancer: ESMO Clinical Practice Guideline for	Consensus	2023	Annals of Oncology	671	Switzerland	Societies

diagnosis, treatment and follow-up ☆						
SARS-CoV-2 variant biology: immune escape, transmission and fitness	Review	2023	Nature Reviews Microbiology	670	UK	UK/non-profit
2023 ACC/AHA/ACCP/HRS Guideline for the Diagnosis and Management of Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines	Consensus	2024	Circulation	628	USA	Societies
Clinical Practice Guideline for the Evaluation and Treatment of Children and Adolescents with Obesity	Consensus	2023	Pediatrics	588	USA	Societies
KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease	Consensus	2024	Kidney International	578	Unclear	Societies
UCSF ChimeraX: Tools for structure building and analysis	Resources	2023	Protein Science	576	USA	NIH/non-profit
Global burden of liver disease: 2023 update	Reference statistics	2023	Journal of Hepatology	575	USA	Institutional/Chile
YaHS: yet another Hi-C scaffolding tool	Resources	2023	Bioinformatics	570	UK	Non-profit
Global estimates of incidence and mortality of cervical cancer in 2020: a baseline analysis of the WHO Global Cervical Cancer Elimination Initiative	Reference statistics	2023	Lancet Global Health	556	France	European
9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes—2023	Consensus	2023	Diabetes Care	556	USA	Societies

CARD 2023: expanded curation, support for machine learning, and resistome prediction at the Comprehensive Antibiotic Resistance Database	Resources	2023	Nucleic Acids Research	533	Canada	Canada/institution/for-profit
Reactive oxygen species, toxicity, oxidative stress, and antioxidants: chronic diseases and aging	Review	2023	Archives of Toxicology	533	Slovakia	Slovakia
The NHGRI-EBI GWAS Catalog: knowledgebase and deposition resource	Resources	2023	Nucleic Acids Research	529	UK	NIH/non-profit/multiple international
Alarming antibody evasion properties of rising SARS-CoV-2 BQ and XBB subvariants	Article	2023	Cell	523	USA	NIH/non-profit/for-profit/institution
Hallmarks of neurodegenerative diseases	Review	2023	Cell	520	Belgium	NIH/non-profit/multiple international
Revolutionizing healthcare: the role of artificial intelligence in clinical practice	Review	2023	BMC Medical Education	512	Saudi Arabia	None
The impact of COVID-19 lockdown on child and adolescent mental health: systematic review	Review	2023	European Child and Adolescent Psychiatry	509	UK	Spain/non-profit/institution
Evaluating the Feasibility of ChatGPT in Healthcare: An Analysis of Multiple Clinical and Research Scenarios	Article	2023	Journal of Medical Systems	504	Italy	Institution
Lobar or Sublobar Resection for Peripheral Stage IA Non-Small-Cell Lung Cancer	Article	2023	New England Journal of Medicine	494	USA	NIH/for-profit
2023 ESC Guidelines for the management of endocarditis	Consensus	2023	European Heart Journal	493	Spain/Germany	Societies
Foundation models for generalist medical artificial intelligence	Article	2023	Nature	491	USA	NIH/NSF/for-profit/non-profit/institution

A practical guide to reflexivity in qualitative research: AMEE Guide No. 149	Consensus	2023	Medical Teacher	490	Colombia	None
2024 Heart Disease and Stroke Statistics: A Report of US and Global Data from the American Heart Association	Reference statistics	2024	Circulation	490	USA	Societies
The molecular and metabolic landscape of iron and ferroptosis in cardiovascular disease	Review	2023	Nature Reviews Cardiology	489	China	NIH/China/institution
Scientific discovery in the age of artificial intelligence	Review	2023	Nature	487	USA	NIH/for-profit/non-profit/institution
2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes	Consensus	2023	European Heart Journal	486	Germany/Italy	Societies
AASLD Practice Guidance on prevention, diagnosis, and treatment of hepatocellular carcinoma	Consensus	2023	Hepatology	485	USA	Societies
Macrophages in immunoregulation and therapeutics	Review	2023	Signal Transduction and Targeted Therapy	483	China/Sweden	China
The roles of extracellular vesicles in the immune system	Review	2023	Nature Reviews Immunology	483	Hungary	Hungary
Diagnosis of myelin oligodendrocyte glycoprotein antibody-associated disease: International MOGAD Panel proposed criteria	Consensus	2023	Lancet Neurology	483	USA	Non-profit/institution
Cancer chemotherapy and beyond: Current status, drug candidates, associated risks and progress in targeted therapeutics	Review	2023	Genes and Diseases	480	Spain/India	Spain

Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction and Obesity.	Article	2023	NEJM	477	USA	For-profit/Germany
Autophagy and autophagy-related pathways in cancer	Review	2023	Nature Reviews Molecular Cell Biology	472	USA/UK	NIH/UK/non-profit
Japanese Gastric Cancer Treatment Guidelines 2021 (6th edition)	Consensus	2023	Gastric Cancer	472	Japan	Societies
The evolution of SARS-CoV-2	Review	2023	Nature Reviews Microbiology	470	UK	European
Personalized RNA neoantigen vaccines stimulate T cells in pancreatic cancer	Article	2023	Nature	465	USA	NIH/non-profit/for-profit/institution
Actin cytoskeleton vulnerability to disulfide stress mediates disulfidptosis	Review	2023	Nature Cell Biology	463	USA	NIH/institution
Global, regional, and national burden of low back pain, 1990–2020, its attributable risk factors, and projections to 2050: a systematic analysis of the Global Burden of Disease Study 2021	Reference statistics	2023	The Lancet Rheumatology	457	Australia	Multiple international/institution
Molecular mechanisms of antibiotic resistance revisited	Review	2023	Nature Reviews Microbiology	457	UK	None
Global Cancer Statistics 2022: the trends projection analysis	Review	2023	Chemical Biology Letters	457	USA/India	None
Proksee: In-depth characterization and visualization of bacterial genomes	Resources	2023	Nucleic Acids Research	456	Canada	Canada

Global Initiative for Chronic Obstructive Lung Disease 2023 Report: GOLD Executive Summary	Consensus	2023	European Respiratory Journal	456	Spain	None
American Geriatrics Society 2023 updated AGS Beers Criteria® for potentially inappropriate medication use in older adults	Consensus	2023	Journal of the American Geriatrics Society	444	USA	Societies
Antimicrobial Resistance: A Growing Serious Threat for Global Public Health	Review	2023	Healthcare (Switzerland)	440	Malaysia	None
Perioperative Pembrolizumab for Early-Stage Non-Small-Cell Lung Cancer	Article	2023	New England Journal of Medicine	435	USA	NIH/for-profit
The WHO estimates of excess mortality associated with the COVID-19 pandemic	Article	2023	Nature	435	Switzerland	UN+WHO
Artificial Intelligence and Machine Learning in Clinical Medicine, 2023.	Review	2023	NEJM	432	Norway	None
Dictionary learning for integrative, multimodal and scalable single-cell analysis	Article	2024	Nature Biotechnology	431	USA	NIH/non-profit
Fast and accurate protein structure search with Foldseek	Resources	2024	Nature Biotechnology	430	Germany/S. Korea	Korea/societies/non-profit
PI3K/AKT/mTOR signaling transduction pathway and targeted therapies in cancer	Review	2023	Molecular Cancer	430	Singapore	Singapore/institution